14th week of 2010 patent applcation highlights part 40 |
Patent application number | Title | Published |
20100087318 | Herbicidal Compositions - The present invention provides an improved herbicidal composition including (a) an effective amount of an herbicidal cyclohexandione oxime compound or agriculturally acceptable salt thereof; (b) one or more esters of a fatty acid; (c) a salt of dodecylbenzensulfonic acid; (d) at least one nonionic surfactant selected from the group consisting of polyoxyethylene plant oils and polyoxyethylene sorbitan esters; and (e) optionally another herbicide. | 2010-04-08 |
20100087319 | Agrochemical Preparations - The invention relates to agrochemical preparations containing (a) active ingredients and (b) esters of hydroxycarboxylic acids. | 2010-04-08 |
20100087320 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS - The present invention relates to novel arylphenyl-substituted cyclic ketoenols of the formula (I) | 2010-04-08 |
20100087321 | Azolylmethyloxiranes, their use for Controlling Phytopathogenic Fungi, and Compositions Comprising Them - The present invention relates to azolylmethyloxiranes of the general formula (I) in which A stands for phenyl which is optionally substituted by one to three of the following substituents: halogen, NO | 2010-04-08 |
20100087322 | ELECTRICITY TRANSMISSION COOLING SYSTEM - A cooling system includes a first section of high temperature superconducting (HTS) cable configured to receive a first flow of coolant and to permit the first flow of coolant to flow therethrough. The system may further include a second section of high temperature superconducting (HTS) cable configured to receive a second flow of coolant and to permit the second flow of coolant to flow therethrough. The system may further include a cable joint configured to couple the first section of HTS cable and the second section of HTS cable. The cable joint may be in fluid communication with at least one refrigeration module and may include at least one conduit configured to permit a third flow of coolant between said cable joint and said at least one refrigeration module through a coolant line separate from said first and second sections of HTS cable. Other embodiments and implementations are also within the scope of the present disclosure. | 2010-04-08 |
20100087323 | Method of enhancing efficacy of electrical apparatuses - The present invention is a method of enhancing efficacy of electrical apparatuses by using the augmented velocity electrons. | 2010-04-08 |
20100087324 | Procedure of densifying filaments for a superconductive wire - A method for producing a superconductive wire, whereby an elongated intermediate element is formed out of an initial element in a deformation step and whereby the superconductive filaments are formed by a final reaction heat treatment, is characterized in that prior to the final reaction heat treatment the filaments in the intermediate element are densified in one or more high pressure densification steps following up the deformation step, said densification steps comprising a simultaneous action of at least four hard surfaces perpendicular to the axis of the elongated intermediate element, building up high pressure P≧100 MPa on a part of the intermediate element having an axial length L. This leads to a substantial increase of the critical current density J | 2010-04-08 |
20100087325 | BIOLOGICAL SAMPLE TEMPERATURE CONTROL SYSTEM AND METHOD - The present invention provides a novel approach for controlling the temperature of biological samples on a support structure. The support structure may, for instance, be a flow cell through which a reagent fluid is allowed to flow and interact with biological samples. A thermoelectric heat exchange device, such as a Peltier device, may be used to heat or cool the biological samples on the support structure. In addition, a fluid circulating heat exchange device, such as a water heating or cooling system, may be used to heat or cool the thermoelectric heat exchange device. In general, the support structure may be located on top of the thermoelectric heat exchange device which, in turn, may be located on top of the fluid circulating heat exchange device. The thermoelectric heat exchange device and fluid circulating heat exchange device may be integrated into a holder bench which may be part of a station within an imaging processing system. The holder bench may be configured to hold multiple support structures at a time. In addition, the support structures may be configured to be evaluated and imaged using both epifluorescent and total internal reflection (TIRF) excitation techniques. | 2010-04-08 |
20100087326 | HETEROCYLIC COMPOUNDS CONTAINING THE MORPHOLINE NUCLEUS THEIR PREPARATION AND USE - Herein are described heterocyclic compounds containing the morpholine nucleus prepared from amino acids, their preparation and use for therapeutic applications. | 2010-04-08 |
20100087327 | PARTICLES - A coated magnetic particle comprising an optionally porous magnetic polymer particle of a matrix polymer, said polymer particle having on a surface and/or in the pores thereof superparamagnetic crystals, said coated particle having a coat formed of a coating polymer, wherein said coated magnetic particle is essentially non-autofluorescent. | 2010-04-08 |
20100087328 | BRM EXPRESSION AND RELATED DIAGNOSTICS - The present invention relates to methods and compounds for causing BRM re-expression in cells, such as cancer cells, that have lost BRM expression. In particular, the present invention relates to screening methods for identifying BRM expression-promoting compounds. The present invention also relates to methods of accessing cancer risk through the identification of polymorphisms in the BRM promoter. | 2010-04-08 |
20100087329 | Enzymatic Labeling of RNA - Methods are described in which a sample containing RNA is contacted with an enzyme having an RNA ligation activity in the presence of a labeled substrate to provide labeled RNA. Methods of performing an array analysis of a labeled RNA sample are also described. | 2010-04-08 |
20100087330 | BREAST CANCER GENE ARRAY - The present invention relates to a method for prognosing or classifying cancer subtypes in a subject with breast cancer. Methods and biomarkers are disclosed that are useful for prognosing or classifying ESR1, PGR and ERBB2 breast cancer subtypes. | 2010-04-08 |
20100087331 | METHOD OF NUCLEIC ACID ANALYSIS - A method of nucleic acid analysis includes the stages of synthesizing a first complementary DNA strand from a messenger RNA using compound primers, synthesizing a second DNA strand, labeling by in vitro transcription of an RNA polymerase, and determining the presence of splicing events in the sample. The present invention has application, for example, in analyzing differential splicing events and in diagnosing diseases. | 2010-04-08 |
20100087332 | High-Throughput High-Information Content Label-Free Cell Biology Screening Methods - A method for hit compound identification in a high throughput, label-free biosensor cellular assay, one method including, for example:
| 2010-04-08 |
20100087333 | PROCESS OF FABRICATING TISSUE ARRAY BLOCK, PROCESS OF FABRICATING TISSUE ARRAY SHEET, TISSUE ARRAY BLOCK, TISSUE ARRAY CHIP, SYSTEM OF FABRICATING TISSUE ARRAY BLOCK AND SYSTEM OF FABRICATING TISSUE ARRAY SHEET - [Task] A process of fabricating a tissue array block; a process of fabricating a tissue array sheet; a tissue array block; a tissue array chip; a system of fabricating a tissue array block; and a system of fabricating a tissue array sheet are proposed, in which the tissue array block can be fabricated even in the case of that having a small thickness, is little affected by tissue hardness and, when having been processed into a tissue array chip, does not suffer any defect in a piece of tissue or at a site of interests, enables the collection of pieces of tissue from a dispersed area, also enables the establishment of positional relationship between the inside of a tissue piece and the inside of a tissue block, and scarcely affects the utilization of the tissue block remaining after collecting the pieces of tissue. | 2010-04-08 |
20100087334 | siRNA targeting superoxide dismutase 1 (SOD1) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1. | 2010-04-08 |
20100087335 | siRNA targeting spleen tyrosine kinase - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. | 2010-04-08 |
20100087336 | FUNCTIONAL NUCLEIC ACIDS AND METHODS - The present invention relates to methods of generating amounts of selective nucleic acids. The present invention further relates to selective nucleic acids incorporated within non-coding nucleic acids, capable of binding to or altering a target molecule. Selective nucleic acids may generally refer to, but are not limited to, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), artificially modified nucleic acids, combinations or modifications thereof. Selective nucleic acids may also generally refer to, but are not limited to, nucleic acid aptamers, aptazymes, ribozymes, deoxyribozymes, nucleic acid probes, small interfering RNAs (siRNAs), micro RNAs (miRNAs), short hairpin RNAs (shRNAs), antisense nucleic acids, diagnostic probes or probe libraries, aptamer inhibitors, precursors of any of the above and/or combinations or modifications thereof. In one aspect, a method for generating amounts of selective nucleic acids includes incorporating a selective nucleic acid sequence into a carrier nucleic acid. In general, the carrier nucleic acid may be transcribed by a cell into a product nucleic acid which may carry an incorporated selective nucleic acid sequence. | 2010-04-08 |
20100087337 | High Throughput Fabrication of Nanoparticles - This application provides a high throughput method of making nanoparticles is provided that utilizes plates comprising wells (e.g., 96-well plates). | 2010-04-08 |
20100087338 | COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES - One or more compositions and methods for inhibiting the formation of hydrate agglomerates in an aqueous medium that contain a specified generic formula are disclosed. The aqueous medium can be contained in an oil or gas pipeline or refinery. | 2010-04-08 |
20100087339 | COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES IN A PROCESS - One or more compositions and methods for inhibiting the formation of hydrate agglomerates in a fluid that contain a specified generic formula are disclosed. The fluid can be contained in an oil or gas pipeline or refinery. | 2010-04-08 |
20100087340 | Methods and Compositions for Inhibiting Metal Corrosion - Methods and compositions are provided that inhibit the corrosion of metal surfaces by aqueous acid solutions. The inhibition is basically achieved by the addition of a reaction product of an alpha,beta-unsaturated aldehyde or ketone with a primary or secondary amine to the aqueous acid solution. | 2010-04-08 |
20100087341 | METHOD OF MANUFACTURING AND USING ROD-SHAPED PROPPANTS AND ANTI-FLOWBACK ADDITIVES - A sintered rod-shaped proppant and anti-flowback agent possesses high strength and high conductivity. The sintered rods comprise between about 0.2% by weight and about 4% by weight aluminum titanate. In some embodiments, the sintered rods are made by mixing bauxitic and non-bauxitic sources of alumina that may also contain several so-called impurities (such as TiO | 2010-04-08 |
20100087342 | ROD-SHAPED PROPPANT AND ANTI-FLOWBACK ADDITIVE, METHOD OF MANUFACTURE, AND METHOD OF USE - A sintered rod-shaped proppant and anti-flowback agent possesses high strength and high conductivity. The sintered rods comprise between about 0.2% by weight and about 4% by weight aluminum titanate. In some embodiments, the sintered rods are made by mixing bauxitic and non-bauxitic sources of alumina that may also contain several so-called impurities (such as TiO | 2010-04-08 |
20100087343 | HYDROPHILIC SURFACES FOR REDUCING FRICTION FORCES - A substrate (for example an implantable medical device) is provided with a lubricious surface by grafting onto the surface monomers containing acrylamide groups and then hydrolysing said groups under alkaline conditions, the grafting step being carried out in an aqueous environment. | 2010-04-08 |
20100087344 | GREASE COMPOSITION AND MACHINE PART - A grease composition which has an excellent anti-fretting property and general versatility, and a machine part which uses the same are provided. A grease composition comprising a urea thickener, a base oil, a phosphorothioate compound and an amine compound and a machine part which uses the same are provided. | 2010-04-08 |
20100087345 | Wax Formulation and Uses Thereof - A wax formulation useful for application on skis, snowboards and other snow sliding apparatus that can be formulated from all natural components and which provides good performance in terms of ease of application, durability during use and lubricity enhancement contains 70 to 100 wt % of base wax composition containing beeswax, and candelilla wax and optionally camauba wax, and up to 30 wt % of one or more additional materials selected from among additional waxes, natural plant oils, hydrogenated plant oils, silicones, and fluoropolymers. In preferred compositions, the additional materials are all of natural origin, thus excluding fluoropolymers and silicones. The amounts of beeswax, camauba wax and candelilla wax in the base wax vary depending on the temperature conditions for which the wax formulation is intended. In general, the base wax composition contains 25-38 wt % beeswax, 50-75 wt % candelilla wax, and 0 to 16 wt % carnauba wax. | 2010-04-08 |
20100087346 | Solid film lubricated high oxidation temperature rhenium material - The present invention provides a composition that includes a rhenium-based alloy and a solid film lubricant. The rhenium-based alloy comprises an alloying substance including at least one constituent having a stronger affinity to oxygen than does Re when exposed to an atmosphere at a temperature of at least about 285° C. | 2010-04-08 |
20100087347 | Detergent - An overbased metal hydrocarbyl-substituted hydroxybenzoate detergent having a basicity index of less than 2 and a degree of carbonation of 80% or greater is disclosed. The overbased metal hydrocarbyl-substituted hydroxybenzoate detergent reduces asphaltene precipitation or ‘black paint’ in a marine diesel engine. | 2010-04-08 |
20100087348 | LUBRICATING OIL COMPOSITION - The present invention provides a lubricating oil composition comprising a mixture of both a poly-alpha-olefin and an ester compound, the lubricating oil composition having an SAE viscosity grade of 75 W-85, satisfying GL-5 in terms of API gear oil designation and having a viscosity index of 160 or more. The above mixture of the poly-alpha-olefin and ester compound is preferably contained in an amount of from 75 to 90 wt % with reference to the total amount of the lubricating oil composition. The poly-alpha-olefin is preferably a mixture of a poly-alpha-olefin having low viscosity of from about 3 to 6 mm | 2010-04-08 |
20100087349 | HVI-PAO bi-modal lubricant compositions - The invention relates to oil compositions containing metallocene catalyzed high viscosity index polyalphaolefins (HVI-PAO). In one embodiment the oil formulation comprises a metallocene catalyzed HVI-PAO with a viscosity greater than 125 cSt kv 100° C. and a viscosity index greater than 100, a second base stock with a viscosity of at least 2 cSt kv 100° C. and less than 60 cSt kv 100° C. wherein the second base stock is at least 60 cSt kv 100° C. less than the metallocene HVI-PAO, an ester with a viscosity of at least 2 and less than 6, the ester comprising more than 10 weight percent and less than 30 weight percent of the oil formulation, the oil formulation having a viscosity index of greater than 195. The use of metallocene catalyzed HVI-PAOs in a bimodal blend provides advantages in improved shear stability, and other properties related to shear stability. | 2010-04-08 |
20100087350 | CAPPED POLYESTER POLYOL LUBRICANT COMPOSITION - The present invention relates to polyester polyol lubricant compositions, some of which are capped, that include two or more chemically linked ester moieties, at least one of which derives from a seed or vegetable oil, and their preparation. The compositions have a pour point temperature of −10° centigrade or less without a pour point depressant and a viscosity at 25° centigrade within a range of 40 centipoises (0.04 pascal second) to 2000 centipoises (2 pascal seconds) when they either lack an initiator moiety or include an initiator moiety other than a dendritic initiator moiety, and a pour point temperature of −5° centigrade or less without a pour point depressant and a viscosity at 25° centigrade within a range of 40 centipoises (0.04 pascal second) to 8000 centipoises (8 pascal seconds) when they include a dendritic initiator moiety. The present invention also relates to a process for removing at least a portion of saturates from said compositions. | 2010-04-08 |
20100087351 | Perfumes for Linear Citrus Release in Rinse-Off Systems - Perfume compositions and method of formulating perfume composition are designed for use in wash-off system with a linear citrus perfume release and either any of the following effects: a desired initial release with minimal residual perfume on the targeted system, a long sustained release of fragrance, or a residual deposition of fragrance after use. | 2010-04-08 |
20100087352 | Process For Creating Shape-Designed Particles In A Fluid - A method for producing particles includes providing a relief template having a surface relief pattern adapted to impart structure to a plurality of particles while they are under production; depositing a radiation-sensitive material on the relief template; exposing portions of the radiation-sensitive material on the relief template using a beam of spatially patterned radiation; removing portions of the radiation-sensitive material after the exposing to reveal at least portions of surfaces of the plurality of particles; and separating at least a portion of the plurality of particles from the relief template. At least a portion of a structure of each of the plurality of particles is defined by a combination of the surface relief pattern and the spatially patterned radiation. | 2010-04-08 |
20100087353 | Novel Variant EGIII-Like Cellulase Compositions - The present invention relates to novel variant EGIII or EGIII-like cellulases that have improved stability. The variant cellulases have performance sensitive residues replaced to a residue having modified stability. | 2010-04-08 |
20100087354 | SPRAYABLE WASH-AND-WAX COMPOSITION - A sprayable wash-and-wax composition which includes biodegradable surfactants and water repelling sealants. The sprayable composition preferably is packaged in an aerosol can and is dispensed as a foamed composition onto the car surface to be cleaned. The foamed composition is thereafter wiped from the car surface to produce a cleaned surface which is then buffed to a high gloss. | 2010-04-08 |
20100087355 | Composition Containing Alpha-Sulfofatty Acid Ester and Hydrotrope and Methods of Making and Using The Same - Compositions containing a α-sulfofatty acid ester and a hydrotrope. The α-sulfofatty acid ester and the hydrotrope reduce the pH drift in the composition and solubilize the α-sulfofatty acid ester in solution. Methods are also disclosed for making such compositions. | 2010-04-08 |
20100087356 | Aromachemicals - Improved aromachemical derivatives, and fragrances and flavorings including the derivatives, that have a longer useful shelf life than the aromachemicals from which they can be derived, are disclosed. In particular, the derivatives maintain the fragrance characteristics of the aromachemicals, while lowering the allergic properties, increasing the stability, and/or increasing the odor intensity. Also disclosed are methods of making the derivatives, and articles of manufacture including the derivatives. In one embodiment, the derivatives are prepared by replacing one or more double bonds in citral with a thioether, cyclopropyl, oxirane, or thiirane group. The cyclopropane ring can be unsubstituted, or substituted with one or two lower alkyl, preferably methyl groups. The alkyl groups can optionally be substituted, for example, with electron donating groups, electron with drawing groups, groups which increase the hydrophilicity or hydrophobocity, and the like. In another embodiment, the derivatives are prepared by replacing the aldehyde group in the essential oil with a nitrile, methyl ether or acetal group. The acetal groups can provide the compounds with a long lasting flavor or fragrance, where the acetals slowly hydrolyze to provide the aldehyde group in the parent essential oil. In some embodiments, both the aldehyde and at least one of the double bond functional groups are both derivatized as described herein. Examples of suitable articles of manufacture include candles, air fresheners, perfumes, disinfectant compositions, hypochlorite (bleach) compositions, beverages such as beer and soda, denture cleanser tablets and flavored orally-delivered products such as lozenges, candies, and the like. | 2010-04-08 |
20100087357 | PERFUME SYSTEMS - The present invention relates to perfume systems, products comprising such systems and the use of same. Unfortunately current perfume systems do not always provide the desired sensory experience. Thus there is a need for one or more perfume systems that obviate the short comings of the current perfume technologies. The systems of the present invention meet the aforementioned need as they employ symbiotic combinations. | 2010-04-08 |
20100087358 | NOTCH mutations leading to increased receptor signaling - The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients. | 2010-04-08 |
20100087359 | USE OF TRYPTOPHAN RICH PEPTIDES - The novel use of peptides derived from whey protein hydrolysate as active ingredient in a medicament or as food ingredient for elevating the cholescystokinin level in the blood, and for preventing or treatment of overweight and/or obesity, in an animal, including human, in need thereof. | 2010-04-08 |
20100087360 | Heterocycle-substituted benzimidazole derivative - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein X | 2010-04-08 |
20100087361 | METHOD TO ENHANCE HEMODYNAMIC STABILITY USING OXYGEN CARRYING COMPOSITIONS - The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance oxygen offloading as a preventative measure to avoid hemodynamic stability-related complications during surgery. | 2010-04-08 |
20100087362 | USE OF BIGLYCAN OR ENHANCERS OF BIGLYCAN ACTIVITY IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS - The present invention relates to the use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and anti-ischemic effect, and to the use of them in methods for preventing and treating the atherosclerotic and ischemid (e.g. cardiac) diseases. The invention also relates to screening methods by which biglycan or enhancers of biglycan activity can be identified. | 2010-04-08 |
20100087363 | GLYCAN MODIFIED SOLUBLE RECEPTORS AND BINDING PROTEIN AND THEIR USE - An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc. | 2010-04-08 |
20100087364 | TROPINE MODULATORS OF 5-HT3 RECEPTOR - The present invention relates to new tropine modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof. | 2010-04-08 |
20100087365 | Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof - The present invention is directed to pharmaceutical composition comprising a clear solution or an aqueous mixture, a suspension or a semisolid of at least one peptide compound selected from the group consisting of hGLP-1(7-36)-NH | 2010-04-08 |
20100087366 | GH SECRETAGOGUES AND USES THEREOF - The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject. | 2010-04-08 |
20100087367 | PRODUCTS AND METHODS USING SOY PEPTIDES TO LOWER TOTAL AND LDL CHOLESTEROL LEVELS - Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided. In another exemplary embodiment of the present disclosure, a composition containing an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided. In a related exemplary embodiment of the present disclosure, a method for lowering or reducing cholesterol levels in an individual is provided where a product containing an effective amount of lunasin peptides to an individual is provided and a claim that the product lowers or reduces cholesterol, total cholesterol, LDL cholesterol or lipid levels in an individual that consumes the composition is made. | 2010-04-08 |
20100087368 | TREATING ACUTE RENAL FAILURE WITH SOLUBLE THROMBOMODULIN VARIANTS - The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality. | 2010-04-08 |
20100087369 | COMPOSITION COMPRISING OLIGOGALACTURONANS AND POLYCATIONIC SACCHARIDES - A ‘bioactive’ composition that has one or more oligogalacturonans ((1→4)-α-D-galacturonan) or any other oligosaccharides (oligoguluronans) that may present an ‘egg box’ conformation, this conformation being further stabilized by one or more polycationic saccharide(s), preferably either a chitosan oligosaccharide or a chitosan polysaccharide. A method prepares this composition and it is used, in medical, pharmaceutical, agricultural, nutraceutical, food, feed, textile, cosmetic, industrial and/or environmental applications. | 2010-04-08 |
20100087370 | MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE - The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject. | 2010-04-08 |
20100087371 | Transglutaminase Variants with Improved Specificity - Variants of transglutaminase from | 2010-04-08 |
20100087372 | GROWTH HORMONE SECRETION STIMULATOR - Provided are: an agent for promoting growth hormone-secretion, containing a milk-derived basic protein fraction as an active ingredient, with the promotion of growth hormone-secretion being mediated by the promotion of secretion of ghrelin having an effect for promoting growth hormone-secretion; and a method of promoting the secretion of ghrelin by using a milk-derived basic protein fraction. The agent for promoting growth hormone-secretion may be ingested on a daily basis and is highly safe even with its ingestion for a long period. | 2010-04-08 |
20100087373 | DETECTION AND THERAPY OF BACTERIAL INFECTION CAUSED BY ENTEROBACTERIACEAE - The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal. An antibody and a kit on the basis of the vaccinating method and detecting/diagnosing method are also provided. | 2010-04-08 |
20100087374 | Methods for Treatment and Diagnosis of Pulmonary Diseases Based on the Expression of SERCA2 Protein - The present invention is directed to methods of treatment of cystic fibrosis. The invention includes a method for treatment of cystic fibrosis in a patient by increasing the activity of sarcoendoplasmic reticulum calcium ATPase (SERCA) in a patient. More specifically, the step of increasing SERCA activity can include but is not limited to, administration of SERCA protein or its homologues, gene therapy to restore or enhance SERCA activity, or the administration of compounds stimulating the activity of endogenous SERCA. Reference herein to SERCA, can include in preferred embodiments, the isoform SERCA2, which is the principal lung isoform of SERCA. The present invention is based on the finding that SERCA2 (a calcium pump) is deficient (not 100%) in the lung epithelial cells of cystic fibrosis samples. | 2010-04-08 |
20100087375 | Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins. | 2010-04-08 |
20100087376 | CANCER RELATED ISOFORMS OF COMPONENTS OF TRANSCRIPTION FACTOR COMPLEXES AS BIOMARKERS AND DRUG TARGETS - The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed. | 2010-04-08 |
20100087377 | Compositions and Methods to Prevent Cancer with Cupredoxins - The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from | 2010-04-08 |
20100087378 | Compositions and Methods for Treating Diseases Associate with Angiogenesis and Inflammation - Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or a biologically active derivative thereof Additionally, the invention relates to methods for treating a disease associated with and/or progresses by an inflammatory cytokine-associated inflammation and/or VEGF-associated angiogenesis. | 2010-04-08 |
20100087379 | POLYPEPTIDES OF BOTRYOSPHAERIA RHODINA - The invention relates to functional polypeptides secreted from | 2010-04-08 |
20100087380 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INTESTINAL PERMEABILITY - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 2010-04-08 |
20100087381 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues - The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H | 2010-04-08 |
20100087382 | Inhibitors of Hepatitis C NS3 Protease - Compounds of formula I: | 2010-04-08 |
20100087383 | INTRACEREBRAL OXIDATION INHIBITOR AND USE THEREOF - The present invention relates to an intracerebral oxidation inhibitor for preventing the onset of mental deterioration, which has early therapeutic effects. Specifically, the present invention relates to: an intracerebral oxidation inhibitor comprising a peptide consisting of Leu and Ile or a modified form thereof as an active ingredient; and a prophylactic or therapeutic agent for mental deterioration comprising the peptide consisting of Leu and Ile or a modified form thereof as an active ingredient and having effects of inhibiting intracerebral oxidation. | 2010-04-08 |
20100087384 | JASMONATE BASED ASSAYS FOR IDENTIFYING COMPOUNDS THAT SELECTIVELY INHIBIT MITOCHONDRIAL BOUND HEXOKINASES - The present invention provides compositions comprising compounds that selectively bind to hexokinases thereby promoting dissociation of these enzymes from mitochondria, and methods of use of such compounds and compositions to induce cell death in diseases and disorders characterized by the high levels of mitochondrial bound hexokinase. The present invention further discloses methods and assays for detecting and identifying molecules having these activities. | 2010-04-08 |
20100087385 | APPLICATION OF GLYCYRRHIZIC ACID AND ITS BREAKDOWN PRODUCT GLYCYRRHETINIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the treatment of inflammatory bowel disease is disclosed. Glycyrrhizic acid or glycyrrhetinic acid and glycyrrhizinate or glycyrrhetate can treat inflammatory bowel disease by inhibiting inflammatory reactions and antioxidation. | 2010-04-08 |
20100087386 | TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION - The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided. | 2010-04-08 |
20100087387 | FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER - Compounds (1, 2, 3, 4) according to the formulae shown below: (Formula 1, 2, 3, 4). For General Formula1-4:N=1-Thyminyl,9-Adeninyl,9-Guaninyl,1-Cytosinyl, 5-methyl-1-cytosinyl, 5-trifluoromethyl-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-trifluoromethyl-1-Uracilyl or Formula (A) (12a/12b) wherein for 12a: n=1, Q=CH | 2010-04-08 |
20100087388 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS - The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. | 2010-04-08 |
20100087389 | Sensory Modifier - Sensory modifiers and compositions comprising sensory modifiers are described. The sensory modifiers comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a substantially anhydrous solvent. | 2010-04-08 |
20100087390 | Universal Sensory Structurant - Universal sensory structurants and compositions comprising the same are described. The universal sensory structurants comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a solvent comprising hydroxylated polymer comprising less than about 100 silane repeat units. | 2010-04-08 |
20100087391 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the | 2010-04-08 |
20100087392 | COMPLEXES OF IBUPROFEN, CYCLODEXTRINS AND TERNARY AGENTS AND THE USE THEREOF IN PHARMACEUTICS - The present invention relates to pharmaceutical compositions comprising ibuprofen in the form of an ibuprofen/cyclodextrin/lysine complex having improved pharmacokinetic properties compared with ibuprofen alone, such as a shortened Tmax and an increased Cmax. | 2010-04-08 |
20100087393 | METHODS AND COMPOSITIONS OF INHIBITING COMPLEMENT AND CELLULAR ACTIVATION WITH DEXTRAN SULFATE - A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product. | 2010-04-08 |
20100087394 | Compositions Containing Betaine and Hydrophobic Silica - A free-flowing, substantially dry-to-the-touch, particulate composition comprises (A) finely particulate hydrophobic silicone-treated silica having a surface area of from 80 to 300 m | 2010-04-08 |
20100087395 | COSMETIC PREPARATION - A cosmetic, wherein the cosmetic comprises tetraquistrimethylsiloxysilane represented by the formula (1) | 2010-04-08 |
20100087396 | Novel Compounds Having Selective Inhibiting Effect at GSK3 - The present invention relates to new compounds of formula I | 2010-04-08 |
20100087397 | USE OF LIPID CONJUGATES IN THE TREATMENT OF CONJUNCTIVITIS - In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis. | 2010-04-08 |
20100087398 | DIHYDROPYRIDINE DERIVATIVE FOR TREATING CANCER OR A PRE-CANCEROUS CONDITION AND OTHER CONDITIONS - The use of dihydropyridine-5-phosphonic acid cyclic propylene ester derivatives of formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug in the treatment of cancers, pre-cancerous conditions and other conditions is disclosed, wherein each of R | 2010-04-08 |
20100087399 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER - The present invention provides novel methods of combination therapy of ovarian cancer, pharmaceutical kits and combinations of 9-oxoacridine-10-acetic acid and/or salts and/or esters thereof with one or more chemotherapeutic agents. The proposed combination therapy is useful in enhancing the action of chemotherapeutic agents and their proliferative activity on human ovarian cancer cells. | 2010-04-08 |
20100087400 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof - The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions. | 2010-04-08 |
20100087401 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES - A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food. | 2010-04-08 |
20100087402 | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders - The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects. | 2010-04-08 |
20100087403 | TOPICAL TREATMENT OF SKIN INFECTION - The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting | 2010-04-08 |
20100087404 | METHOD OF TREATING AND PREVENTING HYPERPARATHYROIDISM WITH ACTIVE VITAMIN D ANALOGS - This invention relates to a method for treating or preventing hyperthyroidism secondary to chronic kidney disease by administering a sufficient amount of an active vitamin D analog utilizing a variety of effective treatment protocols. | 2010-04-08 |
20100087405 | FOOD SUPPLEMENTATION COMPOSITION CONTAINING ONE OR MORE VITAMIN D3 COMPOUNDS AND ONE OR MORE MAGNESIUM SALTS - Use of one or more vitamin D | 2010-04-08 |
20100087406 | INDUCTION OF INNATE IMMUNITY BY VITAMIN D3 AND ITS ANALOGS - Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D | 2010-04-08 |
20100087407 | USE OF AROMATASE INHIBITORS - The invention provides a method of thinning the endometrium in a woman by utilizing a therapeutically effective amount of an aromatase inhibitor. | 2010-04-08 |
20100087408 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 2010-04-08 |
20100087409 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID - This invention relates to compositions (e.g., otic compositions) comprising an antibiotic (generally a quinolone or naphthyridinone), corticosteroid, and organic acid (generally a fatty acid). This invention also relates to treatment methods using such a composition, uses of such a composition to make medicaments, and therapeutic kits comprising such a composition. | 2010-04-08 |
20100087410 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS - The invention provides novel β | 2010-04-08 |
20100087411 | SUBSTITUTED SAPOGENINS AND THEIR USE - The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed | 2010-04-08 |
20100087412 | Micronized Eplerenone Compositions - The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials. | 2010-04-08 |
20100087413 | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss - The present invention relates to the use of an 11-β-HSD-type 1 and or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage. | 2010-04-08 |
20100087414 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE - The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5 -difluorophenyl)methylsulfonamide. | 2010-04-08 |
20100087415 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC channel activity. | 2010-04-08 |
20100087416 | AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS - The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract. | 2010-04-08 |
20100087417 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS - The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. | 2010-04-08 |